Evidence map›Paper›PMID 39351974›Full record

ArticleHematological oncology2024

Real-world data for marginal zone lymphoma patients in the French REALYSA cohort: The REALMA study.

C Bommier, M Donzel, C Rossi, L M Fornecker, F Bijou, A Chauchet, L Lebras, L Ysabaert, C Haioun, K Bouabdallah and 17 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Hematological oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

C BommierUniversité Paris Cité, Assistante Publique Hôpitaux de Paris, Hôpital Saint-Louis, Service d'Hémato-Oncologie, Paris, France.ORCID https://orcid.org/0000-0002-5695-911X
M DonzelDepartment of Pathology, Hopital Lyon Sud, Claude Bernard Lyon 1 University, Lyon, France.
C RossiDepartment of Hematology, Centre Hospitalier Universitaire de Dijon Bourgogne, Dijon, France.
L M ForneckerInstitut de Cancérologie Strasbourg Europe (ICANS) and University of Strasbourg, Strasbourg, France.
F BijouDepartment of Hematology, Institut Bergonie, Bordeaux, France.
A ChauchetDepartment of Hematology, Centre Hospitalier Universitaire de Besançon, Besançon, France.
L LebrasDepartment of Hematology, Leon Berard Cancer Center, Lyon, France.
L YsabaertInstitut universitaire du cancer de Toulouse Oncopole, Toulouse, France.
C HaiounLymphoid Malignancies Unit, Assistante Publique Hôpitaux de Paris APHP, Hopital Henri Mondor, Creteil, France.
K BouabdallahHematology and Cell Therapy Department, University Hospital of Bordeaux, Bordeaux, France.
T GastinneDepartment of Hematology, Centre Hospitalier Universitaire de Nantes, Nantes, France.
N MorineauDepartment of Hematology, Centre Hospitalier Départemental Vendée, La Roche-sur-Yon, France.
S AmorimDepartment of Hematology, Hopital Saint Vincent de Paul, Lille, France.
F JardinDepartment of Clinical Hematology, INSERM, Centre Henri Becquerel, Rouen, France.
J AbrahamDepartment of Hematology, Centre Hospitalier Universitaire de Limoges, Limoges, France.
T Lamy de la ChapelleDepartment of Hematology, Centre Hospitalier Universitaire de Rennes, Rennes, France.
R GressinDepartment of Hematology, Centre Hospitalier Universitaire de Grenoble, Institute for Advanced Biosciences, INSERM U1209/CNRS UMR 5309/Grenoble Alpes University, Grenoble, France.
L FouilletDepartment of Hematology, Centre Hospitalier Universitaire de Saint Etienne, Besancon, France.
C FruchartDepartment of Hematology, Centre Hospitalier de Dunkerque, Dunkirk, France.
G OlivierDepartment of Hematology, Centre Hospitalier de Niort, Niort, France.
F MorschhauserDepartment of Hematology, Universite de Lille, Centre Hospitalier Universitaire de Lille, Groupe de Recherche sur les formes Injectables et les Technologies Associées, Lille, France.
F CherblancLymphoma Academic Research Organisation, Hopital Lyon Sud, Pierre-Benite, France.
A BelotLymphoma Academic Research Organisation, Hopital Lyon Sud, Pierre-Benite, France.
S Le GuyaderRegistre des Hémopathies Malignes de la Gironde, Institut Bergonié, University of Bordeaux, Inserm, UMR, Bordeaux, France.
A MonnereauRegistre des Hémopathies Malignes de la Gironde, Institut Bergonié, University of Bordeaux, Inserm, UMR, Bordeaux, France.
H GhesquieresDepartment of Hematology, Hopital Lyon Sud, Claude Bernard Lyon 1 University, Lyon, France.ORCID https://orcid.org/0000-0002-3131-3718
C ThieblemontUniversité Paris Cité, Assistante Publique Hôpitaux de Paris, Hôpital Saint-Louis, Service d'Hémato-Oncologie, Paris, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Marginal Zone Lymphoma (MZL) comprises three subtypes: extranodal MZL (EMZL), splenic MZL (SMZL) and nodal MZL (NMZL). Since clinical trials have limited representativeness, there is a need for real-world data (RWD) evidence in MZL. Real-world data in Lymphoma and survival in Adults (REALYSA) is a prospective multicentric French cohort of newly diagnosed lymphoma patients. This study consists of the first abstraction of MZL patients prospectively included in REALYSA between 12/2018 and 01/2021 with at least 1 year of follow-up. It provides a landscape description of clinical characteristics, initial workup, quality of life and first-line therapy performed in routine practice. Among 207 included patients, 122 presented with EMZL, 51 with SMZL and 34 with NMZL. At baseline, median age was 67 years (range 28-96), and patients reported a favorable global health status (75/100 (IQR 58,83)) - which was higher in NMZL and lower in SMZL patients (p = 0.006).

Indexed as

Lymphoma, B-Cell, Marginal ZoneAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsFemaleFollow-Up StudiesFranceHumansMaleMiddle AgedProspective StudiesRituximabSurvival RateRituximabepidemiologylymphomamarginal zone lymphomareal‐world datareal‐world evidence

Identifiers

PMID39351974
PMCPMC11590051

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.